⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 22, 2022European Journal of Nuclear Medicine and Molecular ImagingOpen Access

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

EudraCT 2011-000,240-16. NCT01456078. https://clinicaltrials.gov/ct2/show/NCT01456078.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sundlöv et al. (2022) studied this question.

synapsesocial.com/papers/69d97dcf0d540cafc5835cd8 https://doi.org/10.1007/s00259-022-05786-w

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1R: A Language and Environment for Statistical ComputingOriginal Research · 2000 · 355,028 citations
2Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine TumorsLate-Phase Clinical Trial · 2017 · 3,297 citations
3ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine NeoplasmsOriginal Research · 2016 · 496 citations
4Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicityCohort Study · 2018 · 253 citations
5Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetryHuman Clinical Trial · 2017 · 210 citations